Progenics Pharmaceuticals Announces Presentation at the 2020 SNMMI Mid-Winter Meeting
16 Janvier 2020 - 3:10PM
Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company
developing innovative targeted medicines and artificial
intelligence to find, fight and follow cancer, today announced that
an abstract highlighting data from its PSMA AI program has been
selected for a moderated poster presentation at the 2020 Society
for Nuclear and Molecular Medicine (SNMMI) Mid-Winter Meeting,
which will be held from January 23 – 25, 2020 in Tampa,
FL.
Date &
Time: January 23, 2020 from 12:15 p.m. to 1:15
p.m. Eastern Time Title: Deep
Learning-Enabled Automated Hotspot Detection from 18F-DCFPyL
(PyL-PSMA) PET/CT in Metastatic Prostate Cancer
About PyL™ for PET Imaging of Prostate
CancerPyL (also known as 18F-DCFPyL) is a fluorinated
PSMA-targeted positron emission tomography (“PET”) imaging agent
that enables visualization of both bone and soft tissue metastases
to determine the presence or absence of recurrent and/or metastatic
prostate cancer.
About PROGENICS
Progenics is an oncology company focused on the
development and commercialization of innovative targeted medicines
and artificial intelligence to find, fight and follow cancer,
including: therapeutic agents designed to treat cancer (AZEDRA®,
1095, and PSMA TTC); prostate-specific membrane antigen (“PSMA”)
targeted imaging agents for prostate cancer (PyL™ and 1404); and
imaging analysis technology (aBSI and PSMA AI). Progenics has three
commercial products, AZEDRA, for the treatment of patients with
unresectable, locally advanced or metastatic pheochromocytoma or
paraganglioma (rare neuroendocrine tumors of neural crest origin)
who require systemic anticancer therapy; and oral and subcutaneous
formulations of RELISTOR® (methylnaltrexone bromide) for the
treatment of opioid-induced constipation, which are partnered with
Bausch Health Companies Inc.
Forward Looking StatementsThis
press release contains projections and other “forward-looking
statements” regarding future events. Statements contained in this
communication that refer to Progenics’ estimated or anticipated
future results or other non-historical facts are forward-looking
statements that reflect Progenics’ current perspective of existing
trends and information as of the date of this communication and
include statements regarding Progenics’ strategic and operational
plans and delivering value for shareholders. Forward looking
statements generally will be accompanied by words such as
“anticipate,” “believe,” “plan,” “could,” “should,” “estimate,”
“expect,” “forecast,” “outlook,” “guidance,” “intend,” “may,”
“might,” “will,” “possible,” “potential,” “predict,” “project,” or
other similar words, phrases or expressions. Such statements are
predictions only and are subject to risks and uncertainties that
could cause actual events or results to differ materially. These
risks and uncertainties include, among others: risks associated
with the proposed merger transaction with Lantheus Holdings, Inc.;
market acceptance for approved products; the risk that the
commercial launch of AZEDRA may not meet revenue and income
expectations; the cost, timing and unpredictability of results of
clinical trials and other development activities and
collaborations; the unpredictability of the duration and results of
regulatory review of New Drug Applications (NDA) and
Investigational NDAs; the inherent uncertainty of outcomes in the
intellectual property disputes such as the dispute with the
University of Heidelberg regarding PSMA-617; our ability to
successfully develop and commercialize products that incorporate
licensed intellectual property; the effectiveness of the efforts of
our partners to market and sell products on which we collaborate
and the royalty revenue generated thereby; generic and other
competition; the possible impairment of, inability to obtain and
costs of obtaining intellectual property rights; possible product
safety or efficacy concerns, general business, financial,
regulatory and accounting matters, litigation and other risks; and
risks related to changes in the composition of our Board of
Directors following the delivery of shareholder consents in
response to the recent consent solicitation conducted by one of our
shareholders. More information concerning Progenics and such risks
and uncertainties is available on its website, and in its press
releases and reports it files with the Securities and Exchange
Commission (the “SEC”), including those risk factors included in
its Annual Report on Form 10-K for the year ended December 31,
2018, as updated in its subsequent Quarterly Reports on Form 10-Q.
Progenics is providing the information in this press release as of
its date and, except as expressly required by law, Progenics
disclaims any intent or obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events or circumstances or otherwise.
Additional information concerning Progenics and
its business may be available in press releases or other public
announcements and public filings made after this press release. For
more information, please visit www.progenics.com. Information on or
accessed through our website or social media sites is not included
in the company’s SEC filings.
ContactMelissa DownsInvestor
Relations(646) 975-2533mdowns@progenics.com
Progenics Pharmaceuticals (NASDAQ:PGNX)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Progenics Pharmaceuticals (NASDAQ:PGNX)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024